SCHEMBL3274358

SCHEMBL3274358

Cc1cc(CO)c(C)c(C)c1C=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
AOX1 Q06278 1/20 0.43
TRIM24 O15164 1/20 0.42
TRIM33 Q9UPN9 1/20 0.42
CYP3A4 P08684 2/20 0.33
MAPT P10636 1/20 0.33
SHBG P04278 1/20 0.33
USP2 O75604 2/20 0.33
NPSR1 Q6W5P4 1/20 0.31
ERN1 O75460 2/20 0.30
IGF1R P08069 1/20 0.30
SRC P12931 1/20 0.30
AXL P30530 1/20 0.30
PTK2 Q05397 1/20 0.30
AURKB Q96GD4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25949702 0.83 CYP3A4 (0.34) MEN1ALDH1A1KMT2AKDM4ELMNA
SCHEMBL13269603 0.78 ALDH1A1 (0.33) ALDH1A1LMNANPSR1
SCHEMBL8625037 0.76 HPGD (0.41) MEN1ALDH1A1KMT2AKDM4ELMNA
SCHEMBL1313257 0.73 CYP3A4 (0.35) MEN1ALDH1A1KMT2AKDM4ELMNA
SCHEMBL357792 0.73 SHBG (0.40) ALDH1A1KDM4EHPGDMAPTSHBG
SCHEMBL6551606 0.73 CYP3A4 (0.38) MEN1ALDH1A1KMT2AKDM4ELMNA
SCHEMBL3269164 0.72 CYP3A4 (0.48) MEN1ALDH1A1KMT2AKDM4ELMNA
SCHEMBL4372628 0.72 KDM4E (0.39) MEN1ALDH1A1KMT2AKDM4ELMNA
SCHEMBL10705397 0.72 KDM4E (0.39) MEN1ALDH1A1KMT2AKDM4ELMNA
Ammonia Solution, Strong SCHEMBL11609824 0.72 SHBG (0.39) ALDH1A1MAPTSHBGNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
EP-1914229-B1 NOVEL CERCOSPORAMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-06-16 EP disclosed
US-20090036492-A1 Novel Cercosporamide Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-02-05 US disclosed
EP-1914229-A1 NOVEL CERCOSPORAMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036492-A1 Novel Cercosporamide Derivative GPR119, CBR3, SLC5A2 MEN1 1138/4885ALDH1A1 381/4885KMT2A 2352/4885
US-20230242471-A1 THYROMIMETICS TPO, THOP1, THRB MEN1 708/4885ALDH1A1 1458/4885KMT2A 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.